Skip to main content
impaact logo Return to homepage
  • Contact
    • Directory
  • About
    • Mission
    • Network Structure
      • Leadership
    • Areas of Research
      • Cure & Immunotherapy
      • Brain & Mental Health
      • Therapeutics
      • Tuberculosis
      • Social Behavioral Scientific Core (SBSC)
    • Early Career Investigator Program
    • Staff Spotlights
    • Funding Acknowledgements
    • Network Sites
      • Study Site Map
  • Studies
    • Research and Study Opportunities
    • Submit a Research Proposal
    • IMPAACT Study Snapshots
  • Community Engagement
    • ICAB Leadership Group
    • IMPAACT Community Advisory Board (ICAB)
    • Operations Center Staff
    • Resources
      • Acronyms
    • Site Community Advisory Boards
    • Community Meetings and Webinars
  • News & Events
    • Events and Conferences
    • IMPAACT Annual Meeting
    • Newsletters
    • Past Conference Presentations
    • Spotlight Series
  • Resources
    • COVID-19 Resources
    • HIV/AIDS Network Coordination (HANC)
    • Lab Center
      • Laboratory Committees
      • Laboratory Guidance Documents
      • Laboratory Resources for Quality Management
      • MiLab Resources
      • Specimen Repository
    • Manual of Procedures
    • Media Release Form
    • Network Logos & Templates
    • Regulatory Resources
    • Training Opportunities
    • NIH Updates
  • Publications
    • Abstracts
    • Manuscripts
  • Enter a search term.
Back to Sites

PHRU Matlosana

Site Number

31976

Address

Tshepong Hospital
Benji Oliphant Rd
MDR TB Unit
Klerksdorp, Matlosana 2574
South Africa

IMPAACT Members at this Site

Tumelo Moloantoa CRS Coordinator
Katlego Motlhaoleng CRS Coordinator
Neil Martinson CRS Leader
Fatima Mayat CTU Coordinator
Glenda Gray CTU Principal Investigator
Lerato Mohapi CTU Principal Investigator
Ravindre Panchia CTU Principal Investigator

Studies at this Site

P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) Given in Combination with an Individualized Rifampin-Resistant Tuberculosis (RR-TB) Therapy in Infants, Children and Adolescents with RR-TB Disease, Living with or without HIV.

DAIDS Number

11884

Research Area

Tuberculosis

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV

DAIDS Number

20721

Research Area

Tuberculosis

Study Status

Closed to Follow Up

IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis

DAIDS Number

38754

Research Area

Tuberculosis

Study Status

Participants Off Study and Primary Analysis Completed
IMPAACT logo Return to homepage

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.

Stay connected with the IMPAACT Network

Follow IMPAACT

Sign up for our newsletter

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Sitemap Privacy Notice

© 2026 IMPAACT Network